G. A. Fleming

发表

HSR Model Deformation Measurements from Subsonic to Supersonic Speeds

A. W. Burner, W. L. Goodman, G. E. Erickson, 1999 .

To help aging populations, classify organismal senescence

G. A. Fleming, G. Church, G. Small, 2019, Science.

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

G. A. Fleming, L. Heinemann, R. Bergenstal, 2019, Diabetes Care.

Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations

G. A. Fleming, L. Heinemann, R. Bergenstal, 2017, Diabetes Care.

Improving the clinical value and utility of CGM systems: issues and recommendations

G. A. Fleming, L. Heinemann, R. Bergenstal, 2017, Diabetologia.

Lactic acidosis in patients with diabetes treated with metformin.

G. A. Fleming, R. Misbin, B. Stadel, 1998, The New England journal of medicine.

A Regulatory Pathway for Medicines That Target Aging

G. A. Fleming, N. Barzilai, Jennifer H Zhao, 2019, Public Policy & Aging Report.

Alternate Approaches for Pediatric Type 1 Diabetes Drug Development and Potential Regulatory Approval: A Perspective

G. A. Fleming, K. Close, L. Dimeglio, 2015, Diabetes Care.

Erratum: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001 (Diabetes (2004) 53 (250-264))

G. A. Fleming, K. Polonsky, H. Kolb, 2004 .

Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders

G. A. Fleming, B. Harvey, 2019, Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease.

Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders

G. A. Fleming, 2015 .

Fetal Harm Due to Paternal Drug Exposure: A Potential Issue in Drug Development

G. A. Fleming, J. Fourcroy, R. Delap, 1996 .

The FDA, regulation, and the risk of stroke.

G. A. Fleming, 2000, The New England journal of medicine.

The inherent challenges of classifying senescence—Response

G. A. Fleming, G. Church, G. Small, 2020, Science.

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

G. A. Fleming, K. Polonsky, H. Kolb, 2004, Diabetes.

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association

G. A. Fleming, R. Bergenstal, M. Evans, 2022, Diabetologia.

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum

G. A. Fleming, J. Tuomilehto, J. Rosenstock, 2016, Diabetes Care.

Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201

G. A. Fleming, J. Tuomilehto, J. Rosenstock, 2017, Diabetes Care.

Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development

G. A. Fleming, F. Mittermayer, J. R. Turner, 2017, Current diabetes reviews.

Challenges in developing endpoints for type 1 diabetes intervention studies

G. A. Fleming, R. Little, K. Herold, 2009, Diabetes/metabolism research and reviews.

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group

G. Alexander Fleming, Reinhard W. Holl, Lutz Heinemann, 2015, Diabetologia.

Metformin-associated lactic acidosis: Current perspectives on causes and risk.

G. A. Fleming, R. DeFronzo, T. Bicsak, 2016, Metabolism: clinical and experimental.

Regulatory Considerations in the Development of Therapies for Diabetic Nephropathy and Related Conditions

G. A. Fleming, 2000 .

Increasing Minority Participation in Clinical Research

G. A. Fleming, K. Getz, L. Agodoa, 2007 .

Biomarkers for the diagnosis of heart failure in people with diabetes: A consensus report from diabetes technology society.

Connie M. Rhee, G. A. Fleming, Lawrence A Leiter, 2023, Progress in cardiovascular diseases.

Corrigendum to "Metformin-associated lactic acidosis: Current perspectives on causes and risk" [Metabolism 65 (2016) 20-29].

G. A. Fleming, R. DeFronzo, T. Bicsak, 2016, Metabolism: clinical and experimental.

Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial.

G. A. Fleming, F. Greenway, M. Zemel, 2021, American journal of therapeutics.

Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.

G. A. Fleming, R. Bergenstal, D. Bruttomesso, 2022, Diabetes care.

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

Francis J. Doyle, G. A. Fleming, B. Bequette, 2022, Journal of diabetes science and technology.

Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs

Lutz Heinemann, G. A. Fleming, L. Heinemann, 2015, Diabetes Care.

Counterpoint—The End Point: Less is More

G. A. Fleming, 2011, Journal of diabetes science and technology.